
XAIR Stock Forecast & Price Target
XAIR Analyst Ratings
Bulls say
Beyond Air Inc. is well-positioned for growth, supported by a completed $5.0 million capital raise that enhances balance sheet flexibility ahead of the anticipated FDA approval of its second-generation LungFit system, which is crucial for its U.S. commercial strategy. The company's focus on enhancing its device platform and expanding international distribution across approximately 40 countries within nine months suggests strong potential for global market penetration, particularly in the treatment of pulmonary conditions and infectious diseases. Additionally, positive preliminary data from its intratumoral ultra-high concentration Nitric Oxide (UNO) therapy highlights a favorable safety profile and early signals of clinical activity, reinforcing the company’s innovative approach to potential oncology applications.
Bears say
Beyond Air Inc faces significant challenges with the launch of its first-generation LungFit system, highlighting issues such as regulatory delays and lack of inter-hospital transport capabilities, which hinder its market entry and adoption. Furthermore, the company's strategic shift to position its UNO device as an immunotherapy enhancer rather than a standalone tool may reflect underlying concerns about its standalone efficacy and market viability. These factors, combined with the effects of pandemic-driven changes on the ventilation landscape, contribute to a negative outlook on the company's financial performance and growth potential.
This aggregate rating is based on analysts' research of Beyond Air Inc and is not a guaranteed prediction by Public.com or investment advice.
XAIR Analyst Forecast & Price Prediction
Start investing in XAIR
Order type
Buy in
Order amount
Est. shares
0 shares